Daiichi and AstraZeneca fight back in cancer drug dispute with Seagen
18-11-2020
AstraZeneca and Daiichi Sankyo to jointly develop another new cancer treatment
30-07-2020
Daiichi Sankyo unit accuses Pharmacosmos of patent infringement
12-02-2020
Pavel Kapysh / Shutterstock.com
US biotechnology company Seagen has accused Japanese pharmaceutical company Daiichi Sankyo of infringing patents with a recently-approved breast cancer drug.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Seagen, Daiichi Sankyo, breast cancer, Enhertu, AstraZeneca, ADCs, cells, FDA
